Drugs

PEER-REVIEWED FEATURE

Efbemalenograstim Alfa: Adis Evaluation

Key Points

- A dimeric recombinant fusion protein being developed by Evive Biotech for the management of chemotherapy-induced neutropenia
- Received its first approval on 6 May 2023 in China
- Approved for reducing the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignant tumors who are treated with myelosuppressive anticancer drugs that are prone to cause febrile neutropenia

Summary

Efbemalenograstim alfa (Ryzneuta™) is a subcutaneously administered recombinant fusion protein that is being developed by Evive Biotech for the management of chemotherapy-induced neutropenia. On 6 May 2023, efbemalenograstim alfa was approved in China for reducing the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignant tumors who are treated with myelosuppressive anticancer drugs that are prone to cause febrile neutropenia. Efbemalenograstim alfa is under regulatory review for the management of chemotherapy-induced neutropenia in the EU and the USA.

Blair, H. A. Drugs. 2023. https://doi.org/10.1007/s40265-023-01911-7